CTSO up $2.50 since EDT AGM and mentioning "Fresenius" oftenSeems we only mentioned it the one day...
The WORST day in Canadian Bio-tech history.....
"just our luck" Back to the Flintstones...
"Is this the ultimate Shleprock Stock"?
Spectral Announces European Distribution Agreement With Fresenius Medical Care for Its Endotoxin Activity Assay (EAA™) Diagnostic
TORONTO, ONTARIO--(Marketwired - Nov. 10, 2015) - Spectral Medical Inc., ("Spectral" or the "Company") (TSX:EDT)(OTCQX:EDTXF), a Phase III company developing the first treatment for patients with septic shock that comprises a therapeutic device guided by a companion diagnostic, today announced that it has entered into a non-exclusive agreement with Fresenius Medical Care Deutschland GmbH to distribute Spectral's FDA approved rapid test for the assessment of endotoxin activity in human whole blood (EAA™) in eight European countries - Germany, Denmark, Sweden, Finland, Norway, Poland, Hungary and the Czech Republic. It is expected that the EAA™ will initially be sold in conjunction with the Toraymyxin™ ("PMX") hemoperfusion cartridge, a medical device which removes endotoxin from the bloodstream, to guide patient treatment. Spectral is now in the final stages of its Phase III registration trial in anticipation of FDA approval for PMX in the United States.
"We are very pleased to have entered into this commercial relationship with Fresenius for our EAA™ diagnostic, which is key to the identification of patients in septic shock who are most likely to benefit from the PMX treatment," said Dr. Gualtiero Guadagni, Vice President of Sales and Marketing for Spectral. "A positive outcome of our large clinical trial would clearly demonstrate the ability to address the huge market potential we see for the combined testing (EAA™) and treatment (PMX) protocol for patients with septic shock," added Dr. Guadagni
Read more at https://www.stockhouse.com/companies/bullboard#ZX35h9CWuQhR7qSr.99